{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+3",
    "query": {
      "intervention": "dose level 3"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 17691,
    "total_pages": 1770,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+3&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T03:44:30.272Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06723236",
      "title": "A Study of MGC028 in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "NSCLC Adenocarcinoma",
        "Cholangiocarcinoma",
        "Pancreatic Carcinoma",
        "Colorectal Carcinoma"
      ],
      "interventions": [
        {
          "name": "MGC028",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2025-02-13",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-09-24T03:44:30.272Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Boston, Massachusetts • Grand Rapids, Michigan + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06723236"
    },
    {
      "nct_id": "NCT04632992",
      "title": "A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Unresectable or Metastatic Solid Malignancy"
      ],
      "interventions": [
        {
          "name": "Entrectinib",
          "type": "DRUG"
        },
        {
          "name": "Inavolisib",
          "type": "DRUG"
        },
        {
          "name": "Alectinib",
          "type": "DRUG"
        },
        {
          "name": "Ipatasertib",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab Emtansine",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf",
          "type": "DRUG"
        },
        {
          "name": "Tucatinib",
          "type": "DRUG"
        },
        {
          "name": "Investigator's Choice of Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Tiragolumab",
          "type": "DRUG"
        },
        {
          "name": "Pralsetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 252,
      "start_date": "2021-01-13",
      "completion_date": "2024-02-27",
      "has_results": true,
      "last_update_posted_date": "2025-01-08",
      "last_synced_at": "2026-09-24T03:44:30.272Z",
      "location_count": 38,
      "location_summary": "Anchorage, Alaska • Oro Valley, Arizona • Hot Springs, Arkansas + 33 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Oro Valley",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04632992"
    },
    {
      "nct_id": "NCT03231371",
      "title": "Coronary Artery Vasculopathy in Pediatric Heart Transplant Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Orthotopic Heart Transplant"
      ],
      "interventions": [
        {
          "name": "Adenosine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bryan Goldstein",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "1 Year to 25 Years"
      },
      "enrollment_count": 22,
      "start_date": "2008-11",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2017-09-26",
      "last_synced_at": "2026-09-24T03:44:30.272Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03231371"
    },
    {
      "nct_id": "NCT05407636",
      "title": "Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "AMD",
        "nAMD",
        "Wet Age-related Macular Degeneration",
        "wAMD",
        "WetAMD",
        "CNV"
      ],
      "interventions": [
        {
          "name": "ABBV-RGX-314 Dose 1",
          "type": "GENETIC"
        },
        {
          "name": "ABBV-RGX-314 Dose 2",
          "type": "GENETIC"
        },
        {
          "name": "Aflibercept (EYLEA®)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "BIOLOGICAL"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "50 Years to 89 Years"
      },
      "enrollment_count": 735,
      "start_date": "2022-01-13",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-09-24T03:44:30.272Z",
      "location_count": 107,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05407636"
    },
    {
      "nct_id": "NCT03326336",
      "title": "Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-syndromic Retinitis Pigmentosa"
      ],
      "interventions": [
        {
          "name": "Gene therapy: GS030-DP AND Medical device: GS030-MD",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "GenSight Biologics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2018-09-26",
      "completion_date": "2027-10-26",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-09-24T03:44:30.272Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03326336"
    },
    {
      "nct_id": "NCT01794000",
      "title": "A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Prasugrel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 341,
      "start_date": "2013-04",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2019-09-25",
      "last_synced_at": "2026-09-24T03:44:30.272Z",
      "location_count": 20,
      "location_summary": "Oakland, California • Palo Alto, California • Hartford, Connecticut + 16 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01794000"
    },
    {
      "nct_id": "NCT02365571",
      "title": "A Study of LY3154207 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "LY3154207",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 64,
      "start_date": "2015-02",
      "completion_date": "2015-05",
      "has_results": false,
      "last_update_posted_date": "2015-06-11",
      "last_synced_at": "2026-09-24T03:44:30.272Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02365571"
    },
    {
      "nct_id": "NCT05634707",
      "title": "Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Primary Brain Tumor",
        "Brain Tumor, Recurrent"
      ],
      "interventions": [
        {
          "name": "Fluoxetine",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "24 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "24 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2023-08-05",
      "completion_date": "2027-06-05",
      "has_results": false,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-09-24T03:44:30.272Z",
      "location_count": 4,
      "location_summary": "San Diego, California • Stanford, California • New York, New York + 1 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05634707"
    },
    {
      "nct_id": "NCT05262400",
      "title": "A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "PF-07220060 + PF-07104091 combination dose escalation",
          "type": "DRUG"
        },
        {
          "name": "PF-07104091 + PF-07220060 + fulvestrant dose expansion",
          "type": "DRUG"
        },
        {
          "name": "PF-07104091 + PF-07220060 + letrozole dose expansion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 235,
      "start_date": "2022-03-14",
      "completion_date": "2027-02-26",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-09-24T03:44:30.272Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Santa Monica, California • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05262400"
    },
    {
      "nct_id": "NCT00788892",
      "title": "Trial of CPX-351 in Newly Diagnosed Elderly AML Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "CPX-351",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "60 Years to 75 Years"
      },
      "enrollment_count": 126,
      "start_date": "2008-10",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2018-01-12",
      "last_synced_at": "2026-09-24T03:44:30.272Z",
      "location_count": 25,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Sacramento, California + 20 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00788892"
    }
  ]
}